Japan To Be Site Of New Trials For Novartis H1N1 Vaccine
This article was originally published in PharmAsia News
Executive Summary
Japan has been chosen by Swiss drug maker Novartis as the third country in which it plans to conduct clinical trials for its H1N1 flu vaccine. Japan has only four companies that can produce vaccine, so the government is considering companies abroad for additional supplies. Novartis, which already has its vaccine in trials in Switzerland and Germany, plans to begin trials in Japan in mid-September, with the Japanese trials to be overseen by the local subsidiary, Novartis Pharma KK. (Click here for more - a subscription may be required